dioctadecylamidospermine has been researched along with 2019 Novel Coronavirus Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 6 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abou-Samra, AB; Al-Dwairi, H; Al-Khal, A; Al-Maslamani, M; Ali, MT; Alimam, ABMA; Alkeldi, AASS; Asaad, NA; Butt, AA; Canlas, EB; Guerrero, MD; Mohamad, AR; Mohammad, MFS; Thomas, AG | 1 |
| Lau, YL; Lee, DHL; Leung, D; Rosa Duque, JS; So, HK; Wong, WHS; Yip, KM | 1 |
| Anastassopoulou, C; Hatziantoniou, S; Maltezou, HC; Theodoridou, K; Tsakris, A; Vasileiou, K | 1 |
| Arndorfer, J; Ball, SW; Barron, MA; Dascomb, K; DeSilva, MB; Dixon, BE; Dunne, MM; Embi, PJ; Fadel, WF; Fireman, B; Gaglani, M; Goddard, K; Grannis, SJ; Grisel, N; Han, J; Irving, SA; Kharbanda, AB; Klein, NP; Konatham, D; Levy, ME; Lewis, N; Liao, IC; McEvoy, C; Murthy, K; Naleway, AL; Natarajan, K; Ong, TC; Patel, P; Rao, S; Reese, SE; Reynolds, S; Rowley, EA; Schrader, KE; Stenehjem, E; Thompson, MG; Valvi, NR; Weber, ZA; Yang, DH; Zerbo, O | 1 |
| Borzakova, SN; Dolzhikova, IV; Dzharullaeva, AS; Erokhova, AS; Esmagambetov, IB; Gintsburg, AL; Gorev, VV; Grousova, DM; Gushchin, VA; Iliukhina, AA; Izhaeva, FM; Khadorich, EA; Kovyrshina, AV; Logunov, DY; Lubenets, NL; Naroditsky, BS; Nikitenko, NA; Osmanov, IM; Ozharovskaia, TA; Popova, O; Shcheblyakov, DV; Shelkov, AY; Tokarskaya, EA; Tukhvatulin, AI; Vlasova, AV; Zorkov, ID; Zrelkin, DI; Zubkova, OV | 1 |
| Binda, F; Bisesti, A; Bruno, M; Calegari, JG; Castaldi, S; Chiappa, L; Gambazza, S; Laquintana, D; Letzgus, M; Pazzaglia, S; Piatti, A; Sottocorno, M; Tiwana, N | 1 |
1 review(s) available for dioctadecylamidospermine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Evaluation of mortality attributable to SARS-CoV-2 vaccine administration using national level data from Qatar.
Topics: COVID-19; COVID-19 Vaccines; Humans; Qatar; SARS-CoV-2; Social Perception; Vaccination | 2023 |
1 trial(s) available for dioctadecylamidospermine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study.
Topics: Adolescent; Child; COVID-19; COVID-19 Vaccines; Humans; Prospective Studies; SARS-CoV-2 | 2023 |
4 other study(ies) available for dioctadecylamidospermine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
COVID-19 vaccines versus pediatric hospitalization.
Topics: Adolescent; BNT162 Vaccine; Child; COVID-19; COVID-19 Vaccines; Hospitalization; Humans; SARS-CoV-2 | 2023 |
Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: Analysis of data reported to EudraVigilance.
Topics: 2019-nCoV Vaccine mRNA-1273; Adolescent; Anaphylaxis; BNT162 Vaccine; Child; Child, Preschool; COVID-19; COVID-19 Vaccines; Humans; Infant; Infant, Newborn; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021.
Topics: Adult; COVID-19; COVID-19 Vaccines; Emergency Service, Hospital; Hospitalization; Humans; RNA, Messenger; SARS-CoV-2; Viral Vaccines | 2023 |
Setting up and managing the largest COVID-19 mass vaccination center in Lombardy, Italy.
Topics: COVID-19; Humans; Italy; Mass Vaccination; Middle Aged; SARS-CoV-2; Vaccination | 2023 |